![PDF) Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection | Rüdiger Hardeland - Academia.edu PDF) Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection | Rüdiger Hardeland - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/84383579/mini_magick20220418-6313-d9myf4.png?1650277791)
PDF) Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection | Rüdiger Hardeland - Academia.edu
![PDF] Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection? | Semantic Scholar PDF] Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8ede5c8c8ad83e1c1c808dde72f8397df7c10735/13-Table4-1.png)
PDF] Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection? | Semantic Scholar
![Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models - ScienceDirect Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0028390820304408-ga1.jpg)
Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models - ScienceDirect
![Researchers identify new melatonin-based molecular targets for design of new drugs against Parkinson's Researchers identify new melatonin-based molecular targets for design of new drugs against Parkinson's](https://www.drugtargetreview.com/wp-content/uploads/shutterstock_459846454.jpg)
Researchers identify new melatonin-based molecular targets for design of new drugs against Parkinson's
![FIG URE 3 Parkinson's disease pathophysiology with melatonin site of... | Download Scientific Diagram FIG URE 3 Parkinson's disease pathophysiology with melatonin site of... | Download Scientific Diagram](https://www.researchgate.net/publication/323518289/figure/fig3/AS:599732342755333@1519998741829/FIG-URE-3-Parkinsons-disease-pathophysiology-with-melatonin-site-of-action.png)
FIG URE 3 Parkinson's disease pathophysiology with melatonin site of... | Download Scientific Diagram
![PDF) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse | Devendra Patel - Academia.edu PDF) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse | Devendra Patel - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/61621343/mini_magick20191227-3997-x2pgo0.png?1577502110)
PDF) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse | Devendra Patel - Academia.edu
![Prolonged-release melatonin improves the quality of sleep of patients with Parkinson's disease - Medivizor Prolonged-release melatonin improves the quality of sleep of patients with Parkinson's disease - Medivizor](https://medivizor.com/blog/wp-content/uploads/2020/07/wapt_image_32612.png)
Prolonged-release melatonin improves the quality of sleep of patients with Parkinson's disease - Medivizor
![Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection - Venkatramanujam Srinivasan, Daniel P. Cardinali, Uddanapalli S. Srinivasan, Charanjit Kaur, Gregory M. Brown, D. Warren Spence, Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection - Venkatramanujam Srinivasan, Daniel P. Cardinali, Uddanapalli S. Srinivasan, Charanjit Kaur, Gregory M. Brown, D. Warren Spence,](https://journals.sagepub.com/cms/10.1177/1756285611406166/asset/images/large/10.1177_1756285611406166-fig1.jpeg)